Loading…
Loading…
iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return but has experienced significantly larger historical drawdowns.
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (IYH), a passively managed exchange traded fund launched on June 12, 2000.
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.
Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.
The iShares U.S. Healthcare ETF provides broad sector exposure with 100 holdings, while the First Trust NYSE Arca Biotechnology Index Fund focuses on a concentrated basket of 30 biotech stocks. The First Trust fund has delivered higher recent returns but experiences greater price volatility.
Fidelity MSCI Health Care Index ETF carries a significantly lower expense ratio of 0.08% compared to 0.38% for iShares U.S. Healthcare ETF Fidelity MSCI Health Care Index ETF provides broader exposure with 334 holdings, while iShares U.S. Healthcare ETF is more concentrated with 100 positions Both funds exhibit similar risk profiles with five-year maximum drawdowns near 18% and nearly identical beta measurements